COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Respond

In this research study, we want to test the safety and effectiveness of an investigational treatment called LOXO-260. LOXO-260 is an investigational (or experimental) drug that may treat certain cancers that are caused by an abnormality in a gene called RET.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Jared Weiss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

22-1289

ClinicalTrials.gov

NCT05241834

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.